Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07252232 · ClinicalTrials.gov registry record · Phase 3
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
A Phase 3 study of Pancreatic Cancer and PDAC - Pancreatic Ductal Adenocarcinoma, sponsored by Revolution Medicines.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 500
- Enrollment target
- 7
- Study locations
NCT07252232 is a Phase 3 study of Pancreatic Cancer and PDAC - Pancreatic Ductal Adenocarcinoma that is actively recruiting participants, run by Revolution Medicines. The registered enrollment target is 500 participants, above the 391-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (28% higher). The trial reports 7 study locations across 7 states.
The verdict
NCT07252232, a Phase 3 study of Pancreatic Cancer and PDAC - Pancreatic Ductal Adenocarcinoma, is actively recruiting participants, sponsored by Revolution Medicines.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 500 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.
Conditions Studied
Interventions
- DRUG daraxonrasib
Study Locations (7)
Connecticut
- Hartford Healthcare - Hartford
Indiana
- Community Health Network - Indianapolis
Missouri
- Saint Luke's Cancer Institute - Kansas City
Ohio
- Taylor Cancer Research Center - Maumee
South Dakota
- Avera Cancer Institute - Sioux Falls
Virginia
- Virginia Cancer Specialists - Fairfax
Puerto Rico
- Pan American Oncology Trials, LLC - San Juan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2025-12-15 |
| Est. Completion | 2030-07-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07252232
The ClinicalTrials.gov registry entry for NCT07252232 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 391-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (28% higher). The listed sponsor is Revolution Medicines, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which daraxonrasib is the first listed.
NCT07252232 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Connecticut, Indiana, Missouri.
Frequently Asked Questions
What is clinical trial NCT07252232 about?
NCT07252232 is a clinical study titled "Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)". The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.
What is the current status of trial NCT07252232?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2025-12-15. Estimated completion is 2030-07-10.
What conditions does trial NCT07252232 study?
This clinical trial studies the following conditions: Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, PDAC, Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Resected Pancreatic Adenocarcinoma.
What interventions are being tested in trial NCT07252232?
The interventions under investigation include: daraxonrasib (DRUG).
Who is sponsoring clinical trial NCT07252232?
This trial is sponsored by Revolution Medicines, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07252232 being conducted?
This trial has 7 study locations across Connecticut, Indiana, Missouri, Ohio, South Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
RECRUITING · Phase 3
-
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
ACTIVE NOT RECRUITING · Phase 3
-
Tele-PancFit: A Multi-site Trial of Video-based Strengthening Exercise Prehabilitation for Patients With Resectable Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
COMPLETED · Phase 3
-
Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer
COMPLETED · Phase 3
Explore more on PlainTrial
Pancreatic Cancer
All registered trials for this condition
PDAC - Pancreatic Ductal Adenocarcinoma
All registered trials for this condition
Connecticut
All trials with a study site in Connecticut
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.